Yliana Penalosa
Family · Chula Vista, CANPI 1053980052
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.7% of the total across 198 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Salix Pharmaceuticals, A Division Of Bausch Health US, LLC at 32.3% of the total. Reporting peaked in 2021 at $2,502 and has fallen 82.6% since, to $435 in 2025. Among family clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 198 payments — averaging $24.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- Redhill Biopharma Inc.$1K
- Novo Nordisk$580
- Daiichi Sankyo Inc.$366
- AbbVie$283
- AstraZeneca$224
- plus $868 from 15 others
What the payments were for
- Consulting fees$4209%
- Travel & lodging$30%
- Food & beverage$4,45391%
- Education$361%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 88 | $1,587 |
| Redhill Biopharma Inc. | 34 | $1,004 |
| Novo Nordisk | 16 | $580 |
| Daiichi Sankyo Inc. | 21 | $366 |
| AbbVie | 8 | $283 |
| AstraZeneca | 4 | $224 |
| Madrigal Pharmaceuticals | 2 | $175 |
| Phathom Pharmaceuticals, Inc. | 2 | $162 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $111 |
| E.r. Squibb & Sons, L.L.C. | 1 | $103 |
| Currax Pharmaceuticals LLC | 5 | $75 |
| Bristol Myers Squibb | 3 | $55 |
| Intra-sana Laboratories | 1 | $50 |
| QOL Medical, LLC | 1 | $24 |
| Braintree Laboratories, Inc. | 1 | $21 |
| Vivus LLC | 1 | $19 |
| Intercept Pharmaceuticals, Inc. | 1 | $18 |
| Ironwood Pharmaceuticals, Inc | 1 | $15 |
| Ambu Inc. | 1 | $13 |
| Xeris Pharmaceuticals, Inc. | 1 | $13 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,912 in reported general payments places this provider in the 90th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 22 | $490 |
Paid to pharmacies, not to this prescriber.
Other family in Chula Vista
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Erin DwyerSan Diego$189K
- Phyllis CasonLos Angeles$187K
- Gabriel SchwartzSan Francisco$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.